A Phase 4 interventional study of Benralizumab in Asthma, sponsored by AstraZeneca. Completed at 25 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 29th largest by enrollment, is the only one that started in 2022, is one of 9 in phase 4, and was the 34th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 188th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2022, is one of 23 in phase 4, and was the 292nd registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.
This is a phase IV, interventional single group, open-label, uncontrolled, prospective, multicenter clinical trial.
This study will be conducted in male and female participants ≥18 years old with established severe eosinophilic asthma as defined by European Respiratory Society (ERS)/American Thoracic Society (ATS) clinical guidelines inadequately controlled by treatment with Inhaled Corticosteroids-Long-acting β2 agonists (ICS-LABA) with or without oral corticosteroids (OCS) or other asthma controller medications.
Each participant will participate in the study for a minimum of 15 weeks and up to 23 weeks.
This study will comprise of:
Screening visit (V0) Visit 1 (V1; week 0; within 1 to 21 days of screening) Visit 2 (V2; week 4 ± 5 days) Visit 3 (V3; week 8 ± 5 days) Visit 4 (V4; week 13 ± 5 days) Follow-up (2 weeks [± 7 days] after V4) - Phone call follow-up. Participants will be discharged from the study after the phone call follow-up is completed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Positive COVID-19 test at V0, COVID-19 disease within 6 weeks before V0 or History of severe COVID-19 disease at any time, defined by the need for Intensive Care Unit stay or Mechanical Ventilation (invasive or non-invasive).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 3 doses of benralizumab having a strength of 30 mg subcutaneously once every 4 weeks (Week 0, Week 4, and Week 8).
Combination Product: Benralizumab
Participants will receive benralizumab subcutaneously.
Also known as: Fasenra
Change From Baseline in Untrimmed Total Mucus Volume at TLC
Change from baseline in airway dynamics after 13 weeks following treatment with benralizumab, using total mucus volume (specific airway volume) at total lung capacity (TLC) measurements from untrimmed airways was assessed.
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC
Change from baseline in untrimmed total mucus plugs score at TLC was assessed. Mucus plugs was scored with a scoring system similar to that by Dunican et al. with the Severe Asthma Research Program (SARP) based on bronchopulmonary segmental anatomy. The mucus score was calculated by counting the number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of the airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug\[s\] present) or 0 (mucus plug\[s\] absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores indicate worse outcome.
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Air Trapping at FRC
Change from baseline in untrimmed total air trapping at FRC was assessed.
Time frame: Baseline and Week 13
Change From Baseline in Trimmed Distal Airway Wall Volume at TLC
Change from baseline in trimmed distal airway wall volume at TLC was assessed. Change from baseline in airway dynamics at Week 13 following treatment with benralizumab as measured by secondary FRI endpoints, irrespective of participants characteristics was assessed.
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Distal Airway Volume at TLC
Change from baseline in untrimmed distal airway volume at TLC was assessed.
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Distal Airway Volume at Functional Residual Capacity (FRC)
Change from baseline in untrimmed distal airway volume at FRC was assessed.
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Lung Volume at TLC
Change from baseline in untrimmed total lung volume at TLC was assessed.
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Lung Volume at FRC
Change from baseline in untrimmed total lung volume at FRC was assessed.
Time frame: Baseline and Week 13
Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1)
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% confidence interval (CI) for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FEV1
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FEV1
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FEV1
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FEV1
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FEV1
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FEV1
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FEV1
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Vital Capacity (Pre-BD FVC)
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FVC
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FVC
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FVC
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FVC
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FVC
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FVC
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FVC
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
Time frame: At Baseline (Week 0)
Change From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FEV1
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FEV1
Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FEV1
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
Time frame: Baseline and Week 13
Change From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FEV1
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FEV1
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FEV1
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FVC
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FVC
Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FVC
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
Time frame: Baseline and Week 13
Change From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FVC
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FVC
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
Time frame: Baseline and Week 13
Change From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FVC
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
Time frame: Baseline and Week 13
Number of Participants With Adverse Events (AEs)
The safety and tolerability of benralizumab was assessed.
Time frame: From screening (Day -21) to follow-up (up to 1.9 years)
This study was conducted between 11 October 2022 to 19 July 2024 at 24 study centers in in Australia, Belgium, France, Portugal, Spain, United Kingdom, and United States.
| Milestone | Benralizumab |
|---|---|
| Started | 45 |
| Completed | 42 |
| Not completed | 3 |
| Withdrew: Adverse event | 3 |
Change from baseline in airway dynamics after 13 weeks following treatment with benralizumab, using total mucus volume (specific airway volume) at total lung capacity (TLC) measurements from untrimmed airways was assessed.
| Milliliters (mL) | Benralizumab |
|---|---|
| All participants | -0.1279 ± 0.4199 |
| Participants with >=4 mucus plugs | -0.1822 ± 0.4977 |
| Participants with <4 mucus plugs | -0.0056 ± 0.0111 |
| OCS-dependent participants | -0.1619 ± 0.4627 |
| Non-OCS-dependent participants | -0.1260 ± 0.4244 |
Change from baseline in untrimmed total mucus plugs score at TLC was assessed. Mucus plugs was scored with a scoring system similar to that by Dunican et al. with the Severe Asthma Research Program (SARP) based on bronchopulmonary segmental anatomy. The mucus score was calculated by counting the number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of the airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug\[s\] present) or 0 (mucus plug\[s\] absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores indicate worse outcome.
| Scores on a scale | Benralizumab |
|---|---|
| Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC | -11.0 ± 32.8 |
Change from baseline in untrimmed total air trapping at FRC was assessed.
| Percentage of air trapping | Benralizumab |
|---|---|
| Change From Baseline in Untrimmed Total Air Trapping at FRC | -0.1410 ± 12.1660 |
Change from baseline in trimmed distal airway wall volume at TLC was assessed. Change from baseline in airway dynamics at Week 13 following treatment with benralizumab as measured by secondary FRI endpoints, irrespective of participants characteristics was assessed.
| mL | Benralizumab |
|---|---|
| Change From Baseline in Trimmed Distal Airway Wall Volume at TLC | -0.9386 ± 6.1359 |
Change from baseline in untrimmed distal airway volume at TLC was assessed.
| mL | Benralizumab |
|---|---|
| Change From Baseline in Untrimmed Distal Airway Volume at TLC | 1.1225 ± 4.5836 |
Change from baseline in untrimmed distal airway volume at FRC was assessed.
| mL | Benralizumab |
|---|---|
| Change From Baseline in Untrimmed Distal Airway Volume at Functional Residual Capacity (FRC) | 0.5079 ± 1.9741 |
Change from baseline in untrimmed total lung volume at TLC was assessed.
| Liters (L) | Benralizumab |
|---|---|
| Change From Baseline in Untrimmed Total Lung Volume at TLC | 0.0287 ± 0.4416 |
Change from baseline in untrimmed total lung volume at FRC was assessed.
| Liters (L) | Benralizumab |
|---|---|
| Change From Baseline in Untrimmed Total Lung Volume at FRC | -0.0275 ± 0.5101 |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% confidence interval (CI) for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) | -0.2710 (-0.5260 to 0.0352) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FEV1 | -0.2795 (-0.5326 to 0.0260) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FEV1 | -0.6892 (-0.8210 to -0.4742) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FEV1 | 0.5380 (0.2738 to 0.7205) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FEV1 | 0.6556 (0.4360 to 0.7958) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FEV1 | 0.4357 (0.1383 to 0.6548) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FEV1 | 0.2122 (-0.0966 to 0.4799) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FEV1 | -0.1655 (-0.4519 to 0.1560) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Vital Capacity (Pre-BD FVC) | -0.0471 (-0.3421 to 0.2574) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FVC | -0.0273 (-0.3247 to 0.2756) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FVC | -0.3432 (-0.5886 to -0.0311) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FVC | 0.5476 (0.2863 to 0.7269) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FVC | 0.6110 (0.3742 to 0.7670) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FVC | 0.4706 (0.1806 to 0.6789) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FVC | 0.4947 (0.2227 to 0.6891) |
The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.
| Correlation coefficient | Benralizumab |
|---|---|
| Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FVC | 0.1451 (-0.1761 to 0.4354) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
| mL | Benralizumab |
|---|---|
| No adjustment for pre-BD FEV1 | 0.05 (0.00 to 0.11) |
| Adjusted for pre-BD FEV1 | 0.06 (0.00 to 0.12) |
Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.
| Scores on a scale | Benralizumab |
|---|---|
| No adjustment for pre-BD FEV1 | 4.38 (-2.87 to 11.63) |
| Adjusted for pre-BD FEV1 | 5.97 (-1.75 to 13.69) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
| Percentage of air trapping | Benralizumab |
|---|---|
| No adjustment for pre-BD FEV1 | 3.18 (-3.65 to 10.01) |
| Adjusted for pre-BD FEV1 | 5.24 (-1.23 to 11.71) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
| mL | Benralizumab |
|---|---|
| No adjustment for pre-BD FEV1 | 5.29 (-1.39 to 11.97) |
| Adjusted for pre-BD FEV1 | 5.61 (-1.27 to 12.48) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
| mL | Benralizumab |
|---|---|
| Untrimmed distal airway volume at TLC: No adjustment for pre-BD FEV1 | 2.20 (-1.09 to 5.49) |
| Untrimmed distal airway volume at TLC: Adjusted for pre-BD FEV1 | 0.61 (-2.65 to 3.88) |
| Untrimmed distal airway volume at FRC: No adjustment for pre-BD FEV1 | -1.28 (-2.82 to 0.27) |
| Untrimmed distal airway volume at FRC: Adjusted for pre-BD FEV1 | -1.52 (-3.14 to 0.09) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).
| Litre | Benralizumab |
|---|---|
| Untrimmed total lung volume at TLC: No adjustment for pre-BD FEV1 | 0.11 (-0.62 to 0.84) |
| Untrimmed total lung volume at TLC: Adjusted for pre-BD FEV1 | 0.13 (-0.61 to 0.88) |
| Untrimmed total lung volume at FRC: No adjustment for pre-BD FEV1 | 0.52 (-0.16 to 1.21) |
| Untrimmed total lung volume at FRC: Adjusted for pre-BD FEV1 | 0.37 (-0.25 to 0.99) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
| mL | Benralizumab |
|---|---|
| No adjustment for pre-BD FVC | 0.05 (0.00 to 0.11) |
| Adjusted for pre-BD FVC | 0.05 (-0.01 to 0.11) |
Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.
| Scores on a scale | Benralizumab |
|---|---|
| No adjustment for pre-BD FVC | 4.38 (-2.87 to 11.63) |
| Adjusted for pre-BD FVC | 4.65 (-3.00 to 12.30) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
| Percentage of air trapping | Benralizumab |
|---|---|
| No adjustment for pre-BD FVC | 3.18 (-3.65 to 10.01) |
| Adjusted for pre-BD FVC | 4.36 (-2.06 to 10.79) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
| mL | Benralizumab |
|---|---|
| No adjustment for pre-BD FVC | 5.29 (-1.39 to 11.97) |
| Adjusted for pre-BD FVC | 6.08 (-0.60 to 12.76) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
| mL | Benralizumab |
|---|---|
| Untrimmed distal airway volume at TLC: No adjustment for pre-BD FVC | 2.20 (-1.09 to 5.49) |
| Untrimmed distal airway volume at TLC: Adjusted for pre-BD FVC | 1.22 (-2.30 to 4.73) |
| Untrimmed distal airway volume at FRC: No adjustment for pre-BD FVC | -1.28 (-2.82 to 0.27) |
| Untrimmed distal airway volume at FRC: Adjusted for pre-BD FVC | -1.28 (-2.93 to 0.37) |
The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).
| Litre | Benralizumab |
|---|---|
| Untrimmed total lung volume at TLC: No adjustment for pre-BD FVC | 0.11 (-0.62 to 0.84) |
| Untrimmed total lung volume at TLC: Adjusted for pre-BD FVC | 0.11 (-0.63 to 0.85) |
| Untrimmed total lung volume at FRC: No adjustment for pre-BD FVC | 0.52 (-0.16 to 1.21) |
| Untrimmed total lung volume at FRC: Adjusted for pre-BD FVC | 0.40 (-0.22 to 1.02) |
The safety and tolerability of benralizumab was assessed.
| Participants | Benralizumab |
|---|---|
| Any AE | 17 |
| Any serious adverse event (SAE) | 2 |
| Any SAE with outcome death | 0 |
| Any AE leading to discontinuation of study intervention | 1 |
| Any possibly related AE | 3 |
Collected over From screening (Day -21) to follow-up (up to 1.9 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab | 0/45 (0%) | 2/45 (4.4%) | 3/45 (6.7%) |
| Event | Benralizumab |
|---|---|
| Respiratory tract infectionInfections and infestations | 1/45 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/45 |
| Event | Benralizumab |
|---|---|
| GastroenteritisInfections and infestations | 3/45 |
Primary analysis population set consisted portion of the evaluable population that did not have any acute asthma exacerbation nor lower respiratory tract infection during the study period.
| Age, Continuous(Years) | Benralizumab |
|---|---|
| Mean | 54.5 ± 11.4 |
| Sex: Female, Male(Participants) | Benralizumab |
|---|---|
| Female | 23 |
| Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | Benralizumab |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 33 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2022 to primary completion in Jul 2024, 21 months.
Results were first posted in Mar 2025, 8 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 21 months is close to that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab